Hot off the Press!


Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses

​​​​​​Virpax Pharmaceuticals Inc. has chosen Altasciences to conduct preclinical studies in support of their new drug, an intranasal spray called AnQlar™. The drug is intended to prevent the spread of viruses such as influenza, COVID-19 and similar flu-like viruses. The studies were performed at Altasciences’ preclinical facilities located in Columbia, MO, and Scranton, PA, and are currently ongoing.

Altasciences Completes Successful Phase I Trial of Ischemix’ Novel Compound for Treatment of Traumatic Brain Injury (TBI)

​​​​​​A Phase I trial of Ischemix, Inc.’s novel, proprietary cytoprotective drug candidate, CMX-2043, was successfully completed at Altasciences’ clinical facility in Montréal. The study was performed in a group of 80 healthy participants, to evaluate safety, tolerability, and pharmacokinetics of the drug. If successful, CMX-2043 could be a vital step to treating TBI, which is responsible for 60,000 deaths per year in the U.S.

Let's Promote Your Project!

Interested in a custom press release, written by our experts, to feature the great research we do together? Email us to get started!

You may also be interested in:

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining drug development solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services.






Preclinical   —   Clinical   —   Manufacturing and Analytical
Bioanalysis   —   Research Support
Copyright © 2023, Altasciences, All rights reserved.